comprehensive -WSS

comprehensive

author：focus 2025-09-14 10:04:29 - browse：43127

Erik Tokat -- biotech JPM coverage from STAT — Eric Tokat is co-president of investment banking at Centerview Partners. Courtesy Centerview Partners

SAN FRANCISCO — Eric Tokat, biotech’s most prolific dealmaker, believes 2024 will be another strong year for acquisitions, driven by Big Pharma’s need to restock pipelines with medicines that can generate sales in the coming years.

That’s not idle speculation. It’s perhaps as close to a guarantee one can get in biotech. Last year, Tokat’s advisory firm, Centerview Partners, was involved in 19 of the 23 biotech transactions valued at $1 billion or more. Two more acquisitions of Centerview clients — Harpoon Therapeutics and Ambrx Biopharma — were announced Monday morning.

“I’m not sure if we’re going to have 23 deals or 25 deals, but I think it’s going to be a good year,” said Tokat, speaking to STAT over coffee on the sidelines of the J.P. Morgan Healthcare Conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： CDC recommends RSV monoclonal antibody for infants

focus

WSS

Why palliative psychiatry is worth discussing

FDA scientists endorse Pfizer/BioNTech Covid

Medicare inequities exacerbate Puerto Rico’s health disparities

He's a Nobel laureate. Critics say he was misleading on Covid

Why palliative psychiatry is worth discussing

PBM reform efforts get punted in Congress

hotspot

comprehensive

hotspot

As demand for Covid shots wanes, Moderna seeks its next success

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Group behind ProMed defends move to subscription

Hepatitis C has a cure — but many Americans still lack access to it

FAA sets up new process for Hawaii air tour operators to fly at lower altitudes after fatal crashes

Medicare details structure of new drug price negotiation program

FDA approves Sage Therapeutics’ rapid

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

He's a Nobel laureate. Critics say he was misleading on Covid

leisure time

Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

When waiting feels immoral: Empathy in the emergency department

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

When waiting feels immoral: Empathy in the emergency department

FDA scientists endorse Pfizer/BioNTech Covid

leisure time

focus

focus

hotspot